Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 6Recruiting 4Unknown 3Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 78Sarcoma 16Gastrointestinal 8Dermatologic 6Tumor-Agnostic 4NET 4Lymphoid 4Endocrine 4Thoracic 3Other solid neoplasm 3Genitourinary 3Gynecologic 2Breast 1

Conditions

Neuroendocrine Tumors 3Gastro-enteropancreatic neuroendocrine tumor 1Frailty 1

Interventions

lutetium Lu 177 dotatate 15Magnetic Resonance Spectroscopy 9Everolimus 8gallium Ga 68 dotatate 6lanreotide 4cabozantinib 4Temozolomide 4Specimen Handling 4Nivolumab 4Lutetium-177 4Lutetium 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4surufatinib 3olaparib 3copper dotatate CU-64 3Somatostatin 3Injections 3Ga(III)-DOTATOC 3Fluorodeoxyglucose F18 3Cyclophosphamide 3Capecitabine 3pembrolizumab 2fludarabine phosphate 2fludarabine 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Sunitinib 2Radiosurgery 2Octreotide 2Drug Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Temozolomide × NET × Clear all
NCT04339036 2025-12-10

CapTemY90

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
70 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT05554003 2024-11-18

MeTe

European Institute of Oncology

Phase 2 Recruiting
46 enrolled
EndocrineNET

Frailty, Neuroendocrine Tumors

NCT06038461 2024-10-01

An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Recruiting
40 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04893785 2024-06-18

CABOTEM

National Cancer Institute, Naples

Phase 2 Recruiting
35 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡